Select Publications

Amar S et al. Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2007;[Epub ahead of print]. Abstract

Bear HD et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24(13):2019-27. Abstract

De Placido S et al. Lapatinib Expanded Access Program (LEAP): Design, operation and initial safety data. San Antonio Breast Cancer Symposium 2007;Abstract 6077.

Geyer CE et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. Proc ASCO 2007;Abstract 1035.

Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract

Joensuu H et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Mamounas EP et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23(12):2694-702. Abstract

Miller KD et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2005a;Abstract 1066.

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc ASCO 2005b. No abstract available

Montemurro F et al. Lapatinib: A dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007a;7(2):257-68. Abstract

Montemurro F et al. Retrospective evaluation of clinical outcomes in HER2-positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib era. San Antonio Breast Cancer Symposium 2007b;Abstract 4057.

Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007;12(7):756-65. Abstract

O’Donovan N, Crown J. EGFR and HER-2 antagonists in breast cancer. Anticancer Res 2007;27(3A):1285-94. Abstract

Osborne CK, Schiff R. Targeting the HER network in breast cancer: Therapeutic successes and failures. San Antonio Breast Cancer Symposium 2007;Abstract MS1-2.

Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 301.

Perez EA et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. Proc ASCO 2006;Abstract 583.

Ritter CA et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13(16):4909-19. Abstract

Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Valabrega G et al. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18(6):977-84. Abstract

 

Home · Search

EDITOR'S NOTE
Another perspective on metastatic breast cancer
Neil Love, MD
- Select publications

INTERVIEWS

Larry Norton, MD
- Select publications

John Mackey, MD
- Select publications

Charles E Geyer Jr, MD
- Select publications

Roundtable Discussions
- Select publications

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office